These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17875193

  • 1. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
    Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC.
    Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC, Westley IS, Morris RG.
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [Abstract] [Full Text] [Related]

  • 5. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status.
    Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, Elliott JM.
    Pharmacogenetics; 2003 Oct; 13(10):627-32. PubMed ID: 14515061
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E, Azanza JR, Sádaba B, Muñoz MJ, Gil I, Campanero MA.
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [Abstract] [Full Text] [Related]

  • 7. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
    Coller JK, Joergensen C, Foster DJ, James H, Gillis D, Christrup L, Somogyi AA.
    Int J Clin Pharmacol Ther; 2007 Jul; 45(7):410-7. PubMed ID: 17725248
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.
    Haage P, Kronstrand R, Josefsson M, Calistri S, van Schaik RHN, Green H, Kugelberg FC.
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
    [Abstract] [Full Text] [Related]

  • 12. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E.
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [Abstract] [Full Text] [Related]

  • 13. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC.
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP.
    Clin Drug Investig; 2011 Mar; 31(3):155-67. PubMed ID: 21288052
    [Abstract] [Full Text] [Related]

  • 16. Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.
    Vieira CP, Neves DV, Coelho EB, Lanchote VL.
    Drug Metab Lett; 2018 Mar; 12(1):68-70. PubMed ID: 29676238
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
    de Moraes NV, Lauretti GR, Coelho EB, Godoy AL, Neves DV, Lanchote VL.
    Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
    [Abstract] [Full Text] [Related]

  • 20. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    Cai WM, Chen B, Cai MH, Chen Y, Zhang YD.
    Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.